---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-22-005590"
form_type: "8-K"
ticker: "XBIO"
cik: "0001534525"
company_name: "Xenetic Biosciences, Inc."
filed_at: "2022-08-12T23:59:59+00:00"
generated_at: "2026-06-24T00:19:59.226385+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Xenetic Biosciences reports Q2 net loss of $2.7M; advances DNase platform toward Phase 1 study

## Summary
- Net loss of approx $2.7M for Q2 2022; R&D expense rose 296% to $2.1M, including $1.3M IPR&D for DNase license.
- Cash balance of $14.9M at quarter end; royalty payments from Takeda sublicensee ~$0.4M (+45% YoY).
- In-licensed DNase-based oncology platform from CLS Therapeutics in April 2022; targeting Phase 1 in pancreatic carcinoma.
- Engaged Catalent for cGMP manufacturing of Phase 1 clinical supply; collaboration with Belgian Volition for NETs-targeted cell therapies.
- Bolstered IP with U.S. patent for XCART platform covering co-administration of CAR T cells with personalized vaccine.

## SEC filing metadata
- accession: 0001683168-22-005590
- form_type: 8-K
- ticker: XBIO
- cik: 0001534525
- company_name: Xenetic Biosciences, Inc.
- filed_at: 2022-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534525/000168316822005590/0001683168-22-005590-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534525/000168316822005590/xenetic_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-22-005590
- JSON: https://secwatch.observer/filing/0001683168-22-005590.json
- Plain text: https://secwatch.observer/filing/0001683168-22-005590.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.